iBio (NYSEMKT: IBIO)
iBio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
iBio Company Info
iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.
News & Analysis
This Under-the-Radar Pharma Company Could Be a Bargain Hunter's Dream
Pre-clinical successes lead to exclusive licensing agreements for iBio.
Here's Why iBio Stock Surged Friday
Investors are excited about the company's new coronavirus vaccine program.
Why iBio Stock Soared Today
A landmark legal settlement should bolster the biotech's growth prospects.
Why iBio Stock Soared Today
One analyst says investors are underappreciating the biotech's growth prospects.
These 4 Micro-Cap Healthcare Stocks Gained the Most in 2020
Innovation paid off big for investors.
Is It Too Late to Buy iBio Stock?
The time to make money by investing in iBio is over. Here's why that's good news.
3 Popular Robinhood Stocks That Could Realistically Double Within 1 Year
Here's what it would take.
3 Compelling Biotech Stocks to Consider Buying While They're Hot on Robinhood
These companies are certainly risky, but they might have what it takes to deliver serious growth for investors.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.